Morgan Stanley raises Lazard stock price target on acquisition model By Investing.com

Coinbase-related stablecoin yield compromise may help clear the path for a U.S. crypto bill, but the article’s main substance is Morgan Stanley’s updated view on Lazard. The firm lifted its price target to $53 from $52 while keeping an Underweight rating, cut its 2026 EPS estimate by 15% to $2.76, and raised its 2027 EPS estimate to $5.26. Lazard also reported Q1 2026 EPS of $0.42 versus $0.53 expected, while revenue of $757 million beat consensus by 7.17%.

Analysis

The key market implication is not Lazard’s near-term EPS noise, but the optionality embedded in the Caravel integration. If management can actually translate a larger advisory footprint into higher-fee conversion without letting compensation drift above the new assumptions, the stock can rerate from a low-quality cyclical to a “less-bad” compounder — which matters because the market is currently paying for neither growth nor durability. The problem is that the updated margin model implies a fairly tight path to upside; any integration slippage, retention issue, or hiring reset would quickly erase the modest valuation support.

Second-order, the deal mix matters more than the headline revenue add. A bigger advisory platform raises exposure to M&A cycles precisely when capital markets are still selectively open, but it also increases dependence on senior rainmakers and event-driven mandates, making earnings more lumpy and harder to underwrite. That creates a subtle pressure on the dividend thesis: the 4%+ yield is attractive only as long as cash flow remains stable, and any evidence that the payout is being “defended” with lower reinvestment or higher leverage would likely cap the multiple.

For Morgan Stanley, the direct impact is negligible, but the broader takeaway is that sell-side models are still adjusting upward to reflect late-cycle transaction normalization while keeping a defensive posture on bank-like talent costs. That suggests the market is likely to reward firms with operating leverage and punish those with fixed-cost expansion before the revenue inflects. In that framework, Lazard remains a stock where upside requires a durable M&A upcycle, not just a one-quarter beat.

The contrarian angle is that the current setup may be less bearish than consensus implies if deal issuance and strategic activity improve into next year. With a depressed base and a low multiple, even modest execution in advisory revenue can produce outsized share-price movement; the asymmetry is better than the sell-side target suggests, but only if the company avoids another margin reset.

Key Decisions for Investors

• Long LAZ only on weakness into the next 2-4 weeks, with a 6-12 month horizon: upside is tied to Caravel integration credibility and a sustained M&A rebound; stop if compensation ratio commentary deteriorates or another earnings miss hits.
• Pair trade: long LAZ / short a richer asset-light financial intermediary with less earnings leverage over the next 3-6 months; the relative trade captures upside from an advisory-cycle inflection while hedging market beta.
• Sell downside protection on LAZ via cash-secured puts around the current range for 1-2 quarters if you want income exposure; the dividend and low multiple provide a buffer, but only if you are comfortable owning a value trap risk.
• Avoid chasing MS as a sympathy trade; the read-through is minimal, and any impact is second-order at best. Use MS only as a hedge if taking a broader financials basket long.
• For event-driven accounts, consider a tactical call spread on LAZ expiring after the next earnings cycle; the risk/reward is better than outright stock if the market starts pricing the Caravel revenue contribution before the financials fully show it.